Clinical trial NCT01869816: CTRP3 and Progranulin in Patients With Coronary Artery Disease
Official title: Implications of C1q/TNF-related Protein-3(CTRP-3) and Progranulin in Patients With Acutecoronary Syndrome and Stable Angina Pectoris
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Coronary Artery Disease
Keywords: CTRP-3
progranulin
coronary artery disease
Lead sponsor: Korea University
Sponsor class: OTHER
First posted: 2013-06-05
Enrollment: 362
Sex: ALL
Minimum age (years): 20
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: COHORT
Time perspective: CROSS_SECTIONAL
Sampling method: PROBABILITY_SAMPLE
Study population: Acute coronary syndrome (ACS) patients, who were admitted to the coronary care units of the Division of Cardiology at Guro Hospital in Korea University Medical Center.

Control subjects were recruited from the participants for a routine health check-up in the Health Promotion Center of Korea University Guro Hospital.

Brief summary: Visceral obesity is the one of the major causes of cardiovascular morbidity and mortality in industrialized countries. Adipose tissue secretes various kinds of bioactive molecules termed adipokines which contribute to the development of obesity-related disorders including cardiovascular disease (CVD). Progranulin and CTRP3 are recently discovered novel adipokines. Therefore, the investigators tried to compare circulating CTRP-3 and progranulin levels in patients with CAD and investigated whether CTRP-3 or progranulin is significantly associated with CAD prevalence after adjustment for well-known CAD risk factors.

Detailed description: CTRP-3 (synonyms CORS-26, cartducin and cartonectin) is a potent anti-inflammatory adipokine that inhibits proinflammatory pathways in monocytes and adipocytes. Using a recently developed enzymelinked immunosorbent assay (ELISA), we reported that circulating CTRP-3 levels were elevated in patients with glucose metabolism dysregulation.

Progranulin was identified as a key adipokine mediating high fat diet-induced insulin resistance and obesity through interleukin-6 (IL-6) in adipose tissue. We previously reported that progranulin levels were significantly higher in individuals with type 2 diabetes and were associated with macrophage infiltration in omental adipose tissue. Moreover, the expression of progranulin reduces inflammation and its degradation into granulins peptides enhances inflammation in atherosclerotic plaque, which may contribute to the progression of atherosclerosis There has been no previous report on the implication of CTRP-3 or progranulin in humans with cardiovascular disease (CAD). In the present study, we compared circulating CTRP-3 and progranulin levels in patients with CAD and investigated whether CTRP-3 or progranulin is significantly associated with CAD prevalence after adjustment for well known CAD risk factors.

Eligibility criteria: Inclusion Criteria:

* acute myocardial infarction
* unstable angina
* stable angina pectoris

Exclusion Criteria:

For control group, we exclude the participants who had

* a history of CVD (myocardial infarction, unstable angina, stroke, or cardiovascular revascularization)
* type 2 diabetes
* stage 2 hypertension (resting blood pressure, ≥160/100 mmHg)
* malignancy
* severe renal or hepatic disease

Primary outcomes:
measure: CTRP3
timeFrame: 16 months
Secondary outcomes:
measure: SBP
timeFrame: 16 months
measure: LDL cholesterol
timeFrame: 16 months
measure: hsCRP
timeFrame: 16 months
measure: creatinine
timeFrame: 16 months
Other outcomes:
Locations:
city: Seoul
country: Korea, Republic of
facility: Korea University Guro Hospital Dept. of Endocrinology
Study officials:
affiliation: Korea University
name: Kyung Mook Choi, M.D.
role: PRINCIPAL_INVESTIGATOR
References: